Loading
UBX-106 is an experimental not disclosed from Ubix Therapeutics, at a stage the company does not state for cancer.
UBX-106 is a not disclosed (company platform is targeted protein degraders) from Ubix Therapeutics. Undisclosed immuno-oncology programme; the company names no target. The company does not state its stage; it is aimed at cancer. No clinical trial naming it is registered on ClinicalTrials.gov. Listed on the company pipeline; the stage bar is graphical and not readable in page text. No registered trial found on ClinicalTrials.gov. It has not been shown to work in people.
Undisclosed immuno-oncology programme; the company names no target.
1.UBX-106 binds its target with one end and an E3 ubiquitin ligase with the other.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"UBX-106" OR ABSTRACT:"UBX-106") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about UBX-106, not a curated reading list.
Shares Ubix Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ubix Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ubix Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/